197 related articles for article (PubMed ID: 37474954)
1. Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indications.
Wex J; Szkultecka-Debek M; Drozd M; King S; Zibelnik N
Orphanet J Rare Dis; 2023 Jul; 18(1):193. PubMed ID: 37474954
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Negative pressure wound therapy for surgical wounds healing by primary closure.
Norman G; Shi C; Goh EL; Murphy EM; Reid A; Chiverton L; Stankiewicz M; Dumville JC
Cochrane Database Syst Rev; 2022 Apr; 4(4):CD009261. PubMed ID: 35471497
[TBL] [Abstract][Full Text] [Related]
4. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
[TBL] [Abstract][Full Text] [Related]
5. Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.
Cifuentes LI; Gattini D; Torres-Robles R; Gana JC
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD011561. PubMed ID: 33522602
[TBL] [Abstract][Full Text] [Related]
6. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
9. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Blonda A; Barcina Lacosta T; Toumi M; Simoens S
Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
[No Abstract] [Full Text] [Related]
13. Negative pressure wound therapy for surgical wounds healing by primary closure.
Webster J; Liu Z; Norman G; Dumville JC; Chiverton L; Scuffham P; Stankiewicz M; Chaboyer WP
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD009261. PubMed ID: 30912582
[TBL] [Abstract][Full Text] [Related]
14. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.
Craig SS; Dalziel SR; Powell CV; Graudins A; Babl FE; Lunny C
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012977. PubMed ID: 32767571
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
[TBL] [Abstract][Full Text] [Related]
16. Negative pressure wound therapy for surgical wounds healing by primary closure.
Norman G; Goh EL; Dumville JC; Shi C; Liu Z; Chiverton L; Stankiewicz M; Reid A
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009261. PubMed ID: 32542647
[TBL] [Abstract][Full Text] [Related]
17. Negative pressure wound therapy for surgical wounds healing by primary closure.
Norman G; Goh EL; Dumville JC; Shi C; Liu Z; Chiverton L; Stankiewicz M; Reid A
Cochrane Database Syst Rev; 2020 May; 5(5):CD009261. PubMed ID: 32356396
[TBL] [Abstract][Full Text] [Related]
18. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
